Catalyst Pharma Highlights Growth Strategy at J.P. Morgan Conference

Catalyst Pharma ( (CPRX) ) has shared an announcement.

On January 12, 2026, Catalyst Pharmaceuticals outlined its growth strategy and operating profile at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing its status as a profitable rare disease therapeutics player with seven consecutive years of profitability through year-end 2024 and expected continued profitability in 2025. Management highlighted double-digit annual revenue growth, more than $700 million in cash and cash equivalents with no funded debt as of year-end 2025, and over $1 billion of capacity earmarked for additional transactions, positioning the company to pursue accretive acquisitions of commercial and late-stage rare disease assets. The presentation detailed strong prescription compliance above 90% for Firdapse and Agamree, a U.S. LEMS market estimated at over $1 billion with roughly 3,600 currently identified patients and a potential prevalence of up to 5,400, and a DMD market of 11,000–13,000 U.S. patients where steroids remain standard of care, underscoring Catalyst’s focus on expanding market penetration through diagnostics, clinical guideline integration, and patient-support infrastructure to sustain its growth trajectory in the rare disease segment.

The most recent analyst rating on (CPRX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and raised revenue guidance are the most significant factors driving the score. The company’s solid technical indicators and reasonable valuation further support a positive outlook. While challenges such as FYCOMPA’s revenue decline exist, the overall financial health and strategic initiatives position the company well for future growth.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, listed on Nasdaq under the ticker CPRX, is a commercial-stage biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing novel medicines for patients with rare diseases. Its U.S. portfolio includes Firdapse, currently the only evidence-based approved treatment for Lambert-Eaton myasthenic syndrome (LEMS), and Agamree, a differentiated corticosteroid for Duchenne muscular dystrophy (DMD), supported by high-touch patient programs through its Catalyst Pathways hub and a buy-and-build strategy targeting rare disease assets with significant peak sales potential.

Average Trading Volume: 1,276,142

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.78B

For detailed information about CPRX stock, go to TipRanks’ Stock Analysis page.